

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2490986 T4**

(12) Oversættelse af ændret
europæisk patentskrift

-
- (51) Int.Cl.: **C 02 F 1/28 (2023.01)** **B 01 D 15/00 (2006.01)** **C 12 N 9/52 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-06-17**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om opretholdelse af patentet i ændret form: **2024-04-24**
- (86) Europæisk ansøgning nr.: **10825598.5**
- (86) Europæisk indleveringsdag: **2010-10-20**
- (87) Den europæiske ansøgnings publiceringsdag: **2012-08-29**
- (86) International ansøgning nr.: **US2010053389**
- (87) Internationalt publikationsnr.: **WO2011050072**
- (30) Prioritet: **2009-10-21 US 253810 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Revance Therapeutics, Inc., 7555 Gateway Boulevard, Newark, CA 94560, USA**
- (72) Opfinder: **RUEGG, Curtis L., 826 Shepard Way, Redwood City, California 94062, USA**
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Fremgangsmåder og systemer til oprensning af ikke-kompleksbundet botulinum-neurotoksin**
- (56) Fremdragne publikationer:
US-A1- 2003 008 367
US-A1- 2004 259 197
US-A1- 2005 238 669
US-A1- 2006 228 780
US-A1- 2007 037 257
GESSLER ET AL: "A new scaleable method for the purification of botulinum neurotoxin type E", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 119, no. 2, 23 September 2005 (2005-09-23), pages 204-211, XP027663511, ISSN: 0168-1656 [retrieved on 2005-09-23]
WO-A1-2011/050072
WO-A2-00/74703
B.R. DASGUPTA et al.: "Purification and Amino Acid Composition of Type A Botulinum Neurotoxin", Toxicon, vol. 22, 1984, pages 415-424,
C.C. SHONE et al.: "Growth of Clostridia and Preparation of Their Neurotoxins", Curr. Top. Microbiol. Immunol., vol. 195, 1995, pages 143-160,
C.K. TSE et al.: "Preparation and Characterisation of Homogenous Neurotoxin Type A from Clostridium botulinum", Eur. J. Biochem., vol. 122, 1982, pages 493-500,
"Chapter 8 - Sephadex ion exchangers" In: "Ion Exchange Chromatography - Principles and Methods", December 1999 (1999-12), Amersham Pharmacia Biotech ISBN: 91970490-3-4 pages 1-8, 61-64,
ISBN 9789197049030 Ion Exchange Chromatography Principles

Fortsættes ...

Ion Exchange Chromatography - Principles and Methods, 1999, pages 1-162 (filed 29.11.2019)
GE HEALTHCARE: "Ion exchange columns and media", Selection Guide, December 2008 (2008-12),
Pharmacia Fine Chemicals, Gel Filtration Theory and Practice 16-19 (November 1981)

DESCRIPTION

Description

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/253,810, filed on October 21, 2009.

FIELD OF THE INVENTION

[0002] This invention relates generally to chromatographic methods for purifying free *botulinum* neurotoxin from cell cultures to produce a high purity, high potency product.

BACKGROUND OF THE INVENTION

[0003] *Botulinum* toxin is a neurotoxic protein produced by the bacterium *Clostridium botulinum*, as well as other *Clostridial* species, such as *Clostridium butyricum*, and *Clostridium baraffi*. The toxin blocks neuromuscular transmission and causes a neuro-paralytic illness in humans and animals, known as botulism. *C. botulinum* and its spores commonly occur in soil and putrefying animal carcasses, and can grow in improperly sterilized or improperly sealed food containers, which are the cause of many botulism cases. Botulism symptoms can include difficulty walking, swallowing, and speaking, and can progress to paralysis of the respiratory muscles and finally death.

[0004] *Botulinum* toxin type A is the most lethal natural substance known to man. In addition to serotype A, six other generally immunologically distinct *botulinum* toxins have been characterized, namely *botulinum* toxin serotypes B, C₁, D, E, F, and G. The different serotypes can be distinguished by neutralization with type-specific antibodies and vary in severity of paralysis they evoke and the animal species they mostly affect. The molecular weight of the *botulinum* toxin protein molecule, for each of the known *botulinum* toxin serotypes, is about 150 kD, composed of an about 100 kD heavy chain joined to an about 50 kD light chain. Nonetheless, the *botulinum* toxins are released by *Clostridial* bacteria as complexes of the 150 kD toxin with one or more non-toxin proteins. For example, *botulinum* toxin type A exists as 900 kD, 500 kD and 300 kD complexes (approximate molecular weights).

[0005] Despite the known toxic effects, *Botulinum* toxin type A is clinically used to treat a variety of indications, including, e.g., neuromuscular disorders characterized by skeletal muscle hyperactivity. For example, BOTOX[®] is the trademark of a *botulinum* toxin type A complex available commercially from Allergan, Inc., of Irvine, Calif. *Botulinum* toxin type A finds use, for

example, in the treatment of essential blepharospasm, strabismus, cervical dystonia, and glabellar line (facial) wrinkles. Other serotypes also have been used clinically. A *botulinum* toxin type B, for example, has been indicated for use in treating cervical dystonia. The *botulinum* toxins are believed to bind with high affinity to the presynaptic membrane of motor neurons, translocate into the neuron, and thereafter block the presynaptic release of acetylcholine.

[0006] The *botulinum* toxin for clinical use is typically isolated from cell culture and various purification approaches have been used. Historically, the toxin is purified in complexed form by a series of precipitation and tangential flow filtration steps. See, e.g., Schantz E. J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiol Rev 1992 March 56(1):80-99. Such approaches have provided relatively low yields, however, typically less than about 10%. Other approaches have used size exclusion, ion exchange, and/or affinity chromatography. See, e.g., Schmidt J. J., et al., Purification of type E botulinum neurotoxin by high-performance ion exchange chromatography, Anal. Biochem. 1986 July; 156(1):213-219; Simpson L. L., et al., Isolation and characterization of the botulinum neurotoxins, Harsman S, ed. Methods in Enzymology. Vol. 165, Microbial Toxins: Tools in Enzymology San Diego, Calif.: Academic Press; vol 165: pages 76-85 (1988); Kannan K., et al., Methods development for the biochemical assessment of Neurobloc (botulinum toxin type B), Mov Disord 2000; 15(Suppl 2):20 (2000); Wang Y.C., The preparation and quality of botulinum toxin type A for injection (BTXA) and its clinical use, Dermatol Las Faci Cosm Surg 2002; 58 (2002); and U.S. Pat. Appl. Publ. No. 2003/0008367.

[0007] Still other approaches have focused on just one of the toxin's heavy or light chains, rather than a complete and biologically active *botulinum* toxin protein. For example, one of the chains is individually synthesized by recombinant means. See, e.g., Zhou L., et al., Expression and purification of the light chain of botulinum neurotoxin A: A single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain, Biochemistry 1995; 34(46):15175-81 (1995); and Johnson S. K., et al., Scale-up of the fermentation and purification of the recombination heavy chain fragment C of botulinum neurotoxin serotype F, expressed in *Pichia pastoris*, Protein Expr and Purif 2003; 32:1-9 (2003). These approaches, however, require extra steps to reform a complete and biologically active *botulinum* toxin protein.

[0008] A more recent approach involves the use of hydrophobic interaction chromatography, mixed mode, and/or ion exchange chromatography to purify a *botulinum* toxin as a complex. See, e.g., U.S. Pat. Nos. 7,452,697 and 7,354,740. Gessler, Journal of Biotechnology, 119 (2005) 204-211, describes a scalable method for the purification of botulinum neurotoxin type E.

US 2006/0228780 A1, published on October 12, 2006, discloses chromatographic processes and systems for purifying a botulinum toxin complex from an animal protein free fermentation medium.

[0009] Accordingly, there is a need in the art for improved purification methods for isolating complete *botulinum* toxin A proteins in stable, biologically active, but non-complexed forms. It is

therefore an object of the invention to provide compositions and methods addressing these and other needs.

[0010] The foregoing discussion is presented solely to provide a better understanding of the nature of the problems confronting the art and should not be construed in any way as an admission as to prior art nor should the citation of any reference herein be construed as an admission that such reference constitutes "prior art" to the instant application.

SUMMARY OF THE INVENTION

[0011] The scope of the invention is defined by the claims. This invention relates to methods for purifying a non-complexed *botulinum* toxin type A (*botulinum* toxin A). In one embodiment, the method comprises purifying crude non-complexed *botulinum* toxin A to obtain a purified non-complexed *botulinum* toxin A. In this embodiment, the method comprises loading an anion exchange column with the crude non-complexed *botulinum* toxin A to capture the non-complexed *botulinum* toxin on the anion exchange column; eluting the non-complexed *botulinum* toxin A with buffer to give an eluent comprising the non-complexed *botulinum* toxin A; loading a cation exchange column with the eluent from the anion exchange column to permit capture of the non-complexed *botulinum* toxin A; and eluting the non-complexed *botulinum* toxin A with another buffer to give an eluent, thereby obtaining a purified non-complexed *botulinum* toxin A.

[0012] In certain embodiments, the *botulinum* toxin A complex is itself obtained by a number of chromatography steps. In some embodiments, a method for obtaining the *botulinum* toxin A complex comprises obtaining a sample comprising a *botulinum* toxin A complex; loading a hydrophobic interaction column with the sample to permit capture of the toxin, wherein the captured *botulinum* toxin A comprises a complexed *botulinum* toxin A; and eluting the complexed *botulinum* toxin A. The non-complexed *botulinum* toxin A is then dissociated from the complex and the non-complexed *botulinum* toxin A is purified according to the method described above. In some embodiments, the sample is obtained by subjecting a fermentation culture comprising *botulinum* toxin A to acid to obtain an acid precipitate, which may be subjected to additional pre-chromatography purification steps, non-limiting examples of which include tangential flow filtration to concentrate the insoluble material of the precipitate, nuclease digest, clarifying centrifugation and/or filtration.

[0013] In some embodiments, the sample is subjected to a nuclease digestion before loading on the hydrophobic interaction column. Preferably, the nuclease is derived in an animal-product-free process, and even more preferably the entire purification process is animal product free or at least substantially animal product free.

[0014] In some embodiments, the sample to be used in the chromatographic separations is preferably a supernatant or filtrate fraction.

[0015] In some preferred embodiments, the purified non-complexed *botulinum* toxin A is at least 98% pure; and/or has an activity of at least 200 LD₅₀ units/ng. In some embodiments, the method produces a yield of at least about 2 mg/L fermentation culture. In other embodiments, the method produces a yield of about 1 to about 2 mg/L fermentation culture.

[0016] These and other aspects of the invention will be better understood by reference to the following detailed description of the invention.

BRIEF DESCRIPTION OF THE FIGURES

[0017] Figure 1 is a summary flow chart comparing one embodiment of a process according to the instant invention for directly purifying a non-complexed *botulinum* toxin (Figure 1A) with a process for purifying a complexed *botulinum* toxin (Figure 1B).

DETAILED DESCRIPTION

[0018] This invention relates to methods for purifying a non-complexed *botulinum* toxin A. In certain embodiments, the method comprises purifying a crude non-complexed *botulinum* toxin A by loading an anion exchange column with the crude non-complexed *botulinum* toxin A to permit capture of the non-complexed *botulinum* toxin A by the anion exchange column. Non-complexed *botulinum* toxin A is then eluted with buffer to give an eluent comprising the non-complexed *botulinum* toxin A. The eluent from the anion column is loaded on a cation exchange column to permit capture of the non-complexed *botulinum* toxin A and the purified non-complexed *botulinum* toxin A is eluted with buffer, thereby obtaining a purified non-complexed *botulinum* toxin A.

[0019] In some embodiments, the invention provides for the purification of non-complexed botulinum toxin A in a relatively small number of steps to produce a high yield, high purity, and high potency product. Processes within the scope of the invention can be used to efficiently produce a stable but non-complexed botulinum toxin A from fermentation cultures. In other embodiments, the method further comprises providing a sample comprising *botulinum* toxin A complex and loading a hydrophobic interaction column with the sample so as to permit capture of the *botulinum* toxin A complex by the hydrophobic interaction column. The *botulinum* toxin A complex is then eluted from the column with buffer. Crude non-complexed *botulinum* toxin A is dissociated from the *botulinum* toxin A complex to obtain a mixture comprising the crude non-complexed *botulinum* toxin A. In this embodiment, the mixture comprising crude non-complexed *botulinum* toxin A is purified to obtain pure or substantially pure *botulinum* toxin A according to the method described above.

[0020] One aspect of this invention is the recognition that a pharmaceutical composition comprising non-complexed *botulinum* toxin as an active ingredient can provide greater purity

compared to one comprising a complexed form. Non-toxin proteins typically associated with a *botulinum* toxin complex can account for about 90% by weight of the complex. Thus, providing a *botulinum* toxin as a complex necessarily includes at least about 90% by weight of impurities. In other words, at least about 80 to about 90% by weight of the pharmaceutical composition will include cell-derived impurities that are not part of the active molecule nor necessary for its biological activity. Such impurities, however, represent cell-derived materials that when administered to a patient may increase the risk of unwanted immunological reactions to the drug; may increase the risk of unwanted side effects; and/or may increase the risk of transmission of pathogenic agents. In contrast, the high purity of a non-complexed product, obtainable by methods and systems described herein, reduces the amount of host cell impurities that may remain in the pharmaceutical composition, thereby reducing the attendant risks of unwanted reactions and/or transmission. Accordingly, processes and systems described herein can provide a *botulinum* toxin in a form more readily suited to the preparation of safer, purer pharmaceutical compositions.

[0021] Moreover, unlike complexed forms, free *botulinum* toxin prepared in accordance with the method described herein does not need to be stabilized for storage in blood-derived products. *Botulinum* toxin type A complex, for example, is typically stabilized in an excipient comprising albumin, which is derived from human blood. For example, BOTOX[®] consists of a purified *botulinum* toxin type A complex, human serum albumin, and sodium chloride packaged in vacuum-dried form. The same is true for Dysport and Xeomin. While screenings reduce likelihood of contamination with pathogenic agents, use of human blood in pharmaceutical preparations generally increases the risk of unwanted transmission of certain pathogenic agents, e.g., agents which are not or cannot yet be screened out. In contrast, free *botulinum* toxin prepared according to the instant invention can be stably stored, as taught herein, in ammonium sulfate. Further, in some preferred embodiments, methods and systems of the instant invention are substantially, essentially, or entirely animal product free, as discussed herein. The ability to also stably store the toxin product substantially, essentially, or entirely animal-product free, further reduces potential risks associated with animal-derived products. Accordingly, processes and systems described herein provide a *botulinum* toxin in a form particularly suited to pharmaceutical applications in terms of safety, e.g., where the pharmaceutical composition may be prepared and stored substantially, essentially, or entirely animal-product free.

[0022] In certain preferred embodiments, the processes described herein are scalable and/or cGMP compliant. Accordingly, methods and systems described herein may be used on a commercial, industrial scale, to produce non-complexed *botulinum* toxin for use, e.g., in pharmaceutical compositions. A cGMP compliant process or system refers to one that can comply with the regulatory requirements for current good manufacturing practices, as required by the U.S. Code of Federal Regulations. In some preferred embodiments, the non-complexed *botulinum* toxin A product is particularly suited to large scale production due to its ease of storage and usability, high activity, high purity, stability, and/or improved safety.

[0023] "*Botulinum* toxin" as used herein refers to a neurotoxin protein molecule that can be

produced by a *Clostridial* bacterium, as well as recombinantly produced forms thereof. A recombinant *botulinum* toxin can have the light chain and/or heavy chain of the toxin protein synthesized via recombinant techniques, e.g., by a recombinant *Clostridial* and/or *non-Clostridial* species. "*Botulinum* toxin" is used interchangeably herein with the related expressions "*botulinum* neurotoxin," "neurotoxin" or simply "toxin." "*Botulinum* toxin" encompasses any of the *botulinum* toxin serotypes A, B, C₁, D, E, F and G, and also encompasses both complexed and non-complexed forms.

[0024] By "complexed form" is meant a *botulinum* toxin complex comprising a botulinum toxin protein (*i.e.*, the toxin molecule with a molecular weight of about 150 kD) as well as at least one associated native non-toxin protein. Non-toxin proteins that make up the complexes typically include non-toxin hemagglutinin protein and non-toxin non-hemagglutinin protein. Thus complexed forms may comprise a *botulinum* toxin molecule (the neurotoxic component) and one or more non-toxin hemagglutinin proteins and/or one or more non-toxin non-hemagglutinin proteins. In certain embodiments, the molecular weight of the complex is greater than about 150 kD. For example, complexed forms of the *botulinum* toxin type A can have molecular weights of about 900 kD, about 500 kD or about 300 kD. Complexed forms of *botulinum* toxin types B and C₁ can have a molecular weight of 500 kD. Complexed forms of *botulinum* toxin type D can have a molecular weight of about 300 kD or about 500 kD. Finally, complexed forms of *botulinum* toxin types E and F can have a molecular weight of about 300 kD.

[0025] "Non-complexed" *botulinum* toxin refers to an isolated, or essentially or substantially isolated, *botulinum* toxin protein having a molecular weight of about 150 kD. That is, "non-complexed" forms exclude non-toxin proteins, such as non-toxin hemagglutinin and non-toxin non-hemagglutinin proteins, normally associated with the complexed form. "Non-complexed" *botulinum* toxin is used interchangeably herein with "free" *botulinum* toxin. All the *botulinum* toxin serotypes made by native *Clostridium botulinum* bacteria are synthesized by the bacteria as inactive single chain proteins which are then cleaved or nicked by proteases to become neuroactive. The protein comprises an about 100 kD heavy chain joined by a disulfide bond to an about 50 kD light chain.

[0026] *Botulinum* toxin complexes can be dissociated into toxin and non-toxin proteins by various means, including, for example, raising the pH to about 7.0, treating the complex with red blood cells at a pH of about 7.3, and/or subjecting the complex to a separation process, such as column chromatography in a suitable buffer at a pH of about 7 to about 8.

[0027] The instant invention encompasses methods that enable purification of a non-complexed *botulinum* toxin A, without associated non-toxin proteins conventionally believed necessary during the purification process to maintain stability. In preferred embodiments, the methods described herein facilitate purification of the free *botulinum* toxin A without loss of stability. By "stability" or "stable" is meant that the *botulinum* toxin protein molecule retains both the about 100 kD heavy chain and the about 50 kD light chain, joined to each other by a disulfide bond, and in a conformation that allows for biological activity.

[0028] In some embodiments, a particular system is operated in conjunction with a particular method within the scope of the present invention. A system used within the scope of the present invention can comprise a plurality (preferably consecutive series) of chromatography columns for use with a corresponding plurality (preferably consecutive series) of chromatography steps. Further, a system used within the scope of the instant invention may comprise a plurality (preferably a consecutive series) of non-chromatography devices, such as filtration and/or centrifugation apparatus, for use with a corresponding plurality (preferably consecutive series) of non-chromatography steps, e.g., as pre-chromatography steps.

[0029] In preferred instances, a process comprises obtaining a sample comprising *botulinum* toxin A from a fermentation culture; subjecting it to a number of pre-chromatography purifications; and then passing it through a plurality of chromatography columns to obtain a highly purified, highly potent non-complexed *botulinum* toxin A. Such a purified free *botulinum* toxin A finds use in the preparation of pharmaceutical compositions comprising the free *botulinum* toxin A as an active ingredient.

[0030] The overall steps for both pre-chromatography and chromatography processes for some preferred embodiments of the instant invention are illustrated in Figure 1A. For comparison, Figure 1B shows a conventional method for obtaining purified *botulinum* toxin complex. Briefly, Figure 1B depicts a process involving depth filtration of a fermentation culture, followed by tangential flow filtration of the filtrate obtained (using 300kD ultrafiltration); followed by a clarifying centrifugation step. The pellet (insoluble fraction) resulting from the centrifugation step is then resuspended in sodium chloride, and loaded onto a hydrophobic interaction or ion exchange column. The chromatographic purification step is repeated at least three times to give a final eluent containing the 900 kD *botulinum* toxin type A complex.

Fermentation and Acid Precipitation

[0031] As Figure 1A illustrates, the non-complexed *botulinum* toxin is generally purified from a fermentation culture. A "fermentation culture" as used herein refers to a culture or medium comprising cells, and/or components thereof, that are synthesizing and/or have synthesized at least one *botulinum* toxin. For example, *Clostridial* bacteria, such as *Clostridium botulinum*, may be cultured on agar plates in an environment conducive to bacterial growth, such as in a warm anaerobic atmosphere. The culture step typically allows *Clostridial* colonies with desirable morphology and other characteristics to be obtained. Selected cultured *Clostridial* colonies then can be fermented in a suitable medium as a fermentation culture. The cultured cells may include *non-Clostridial* species as the host cells, such as *E. coli* or yeast cells, that are rendered capable of biosynthesizing a *botulinum* toxin by recombinant technology. Suitable fermentation culture conditions can depend on the host cells used and are generally known in the art.

[0032] In preferred embodiments, fermentation may be allowed to progress to completion, such that cells are mature and have biosynthesized a *botulinum* toxin. Growth of *Clostridium*

botulinum cultures is usually complete after about 24 to about 36 hours. After a certain additional period of time, the bacteria typically lyse and release into the medium the synthesized *botulinum* toxin complex in a complexed form. For example, during a fermentation of about 60 to about 96 hours, most *Clostridium botulinum* cells undergo lysis and release *botulinum* toxin type A complex.

[0033] In some embodiments, the fermentation culture can comprise one or more animal products, such as animal proteins, used in conventional fermentation culture procedures. For example, *botulinum* toxin can be produced by anaerobic fermentation of *Clostridium botulinum* using a modified version of the well known Schantz process (see e.g. Schantz E. J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiol Rev 1992 March; 56(1):80-99; Schantz E. J., et al., Preparation and characterization of botulinum toxin type A for human treatment, chapter 3 in Jankovic J, ed. Neurological Disease and Therapy. Therapy with botulinum toxin (1994), New York, Marcel Dekker; 1994, pages 41-49, and; Schantz E. J., et al., Use of crystalline type A botulinum toxin in medical research, in: Lewis G E Jr, ed. Biomedical Aspects of Botulism (1981) New York, Academic Press, pages 143-50). Both the Schantz and the modified Schantz process for obtaining a *botulinum* toxin make use of animal products, including animal-derived-Bacto-Cooked Meat medium in the culture vial, and casein in the fermentation media. Additionally, the Schantz toxin purification makes use of DNase and RNase from bovine sources to hydrolyze nucleic acids present in the fermentation culture.

[0034] However, administration of a pharmaceutical containing an active ingredient that was purified using a process involving animal-derived products can subject a patient to a potential risk of receiving various pathogenic agents. For example, prions may be present in a pharmaceutical composition comprising contaminating animal-derived products, such as the prion responsible for Creutzfeldt-Jacob disease. As another example, there is a risk of transmitting a spongiform encephalopathy (TSE), such as a bovine spongiform encephalopathy (BSE) when animal products are used in the process of making a pharmaceutical composition. The use of a *botulinum* toxin obtained via processes free of animal products, however, reduces such risks. Therefore, in some preferred embodiments, the invention provides a process that is free of animal products, or essentially or substantially animal-product-free (APF). "Animal product free", "essentially animal product free", or "substantially animal product free" encompasses, respectively, "animal protein free", "essentially animal protein free", or "substantially animal protein free" and respectively means the absence, essential absence, or substantial absence, of products derived from animals, non-limiting examples of which include products derived from blood or pooled blood. "Animal" is used herein to refer to a mammal (such as a human), bird, reptile, amphibian, fish, insect, spider or other animal species, but excludes microorganisms, such as bacteria and yeasts.

[0035] An animal-product-free process (or a substantially or essentially animal product-free-process) refers to a process that is entirely, substantially, or essentially free of animal-derived products, reagents and proteins, such as immunoglobulins, other blood products, by-products, or digests; meat products, meat by-products, meat digests; and milk or dairy products, by-

products or digests. Accordingly, an example of an animal-product free fermentation culture procedure is a fermentation process, such as bacterial culturing, which excludes blood, meat, and dairy products, by-products, and digests. An animal-product-free fermentation process for obtaining a non-complexed *botulinum* toxin reduces the possibility of contamination with viruses, prions or other undesirable agents, which can then accompany the toxin when administered to humans.

[0036] Animal-product-free fermentation procedures using *Clostridium* cultures are described, e.g., in U.S. Pat. Nos. 7,452,697 and 7,354,740. For example, the growth media for production of the *botulinum* toxin may comprise vegetable-based products, instead of animal-derived products, such as soy-based products and/or the debittered seed of *Lupinus campestris*. Soy-based fermentation media for use in an animal product free fermentation culture, for example, can comprise a soy-based product, a source of carbon such as glucose, salts such as NaCl and KCl, phosphate-containing ingredients such as Na₂HPO₄ and KH₂PO₄, divalent cations such as iron and magnesium, iron powder, amino acids such as L-cysteine and L-tyrosine, and the like. Preferably, the soy is hydrolyzed soy and the hydrolyzation has been conducted using enzymes not derived from animals. Sources of hydrolyzed soy include but are not limited to Hy-Soy (Quest International), Soy peptone (Gibco) Bac-soytone (Difco), AMISOY (Quest), NZ soy (Quest), NZ soy BL4, NZ soy BL7, SE50M (DMV International Nutritionals, Fraser, N.Y.), and SE50MK (DMV).

[0037] As Figure 1A illustrates, in certain embodiments a sample comprising *botulinum* toxin A is obtained from a fermentation culture. For example, after a certain period of fermentation, in either animal product free or non-animal product free media, *botulinum* toxin A complex is released into the medium and can be harvested by precipitation. For example, in some embodiments, as in the well-known Schantz process, the fermentation medium comprising the *botulinum* toxin A may be subjected to acid precipitation to encourage the *botulinum* toxin complexes to associate with cell debris and form an acid precipitate. In some particularly preferred embodiments, about 3 M sulfuric acid solution may be added to the fermentation culture to form the acid precipitate. Preferably, the pH is reduced to about 3 to about 4, more preferably to about 3.2 to about 3.8, and even more preferably about 3.5. In some embodiments, the culture temperature is also reduced, e.g., to about below 25°C, 24°C, 23°C, 22°C, 21°C, or 20°C. These conditions further enhance the association of *botulinum* toxin complexes with cell debris. The acid precipitate formed will comprise bound *botulinum* toxin complexes and can be used as the starting material in further purification steps, such as clarification steps; whereas the filtrate is discarded.

[0038] In contrast, the conventional process depicted in Figure 1B does not include an acid precipitation step. That is, while the purification procedure also begins with a fermentation culture comprising a *botulinum* toxin complex, the culture medium is subjected to depth filtration, and the filtrate, rather than the cell debris, is used in subsequent purification steps. In the Figure 1B process, the cell debris is discarded, rather than the filtrate, whereas, as illustrated in Figure 1A, the filtrate is discarded and the cell debris (acid precipitate) is used for further purification steps, e.g., in the pre-chromatography purifications discussed below.

Pre-Chromatography Purifications

[0039] The sample obtained from the fermentation medium is subjected to one or more pre-chromatography purifications. Pre-chromatography purifications include tangential flow filtration, optionally nuclease digest, and optionally clarifying centrifugation and/or filtration. A non-limiting example of a process flow containing pre-chromatography purification contemplated by the invention is provided in Figure 1A. As noted above, in preferred embodiments, the pre-chromatography procedures are carried out on a precipitate (or insoluble fraction) of a fermentation culture comprising the *botulinum* toxin A, rather than on the fermentation culture itself or on a filtrate derived therefrom, as in the process illustrated in Figure 1B. That is, in preferred embodiments of the invention, pre-chromatography (clarification) steps start with the acid precipitate (insoluble fraction).

[0040] The sample (acid precipitate or insoluble fraction) comprising a *botulinum* toxin A is subjected to tangential flow filtration. Tangential flow filtration is a process typically used to clarify, concentrate, and/or purify proteins. In contrast to normal flow filtration, where fluid moves directly towards a filter membrane under applied pressure, in tangential flow filtration, the fluid moves tangentially along, or parallel to, the surface of the membrane. Applied pressure serves to force a portion of the fluid through the filter membrane, to the filtrate side, while particulates and macromolecules too large to pass through membrane pores are retained. Unlike normal flow filtration, however, the retained components do not build up at the membrane surface but are swept along by the tangentially flowing fluid. In certain preferred embodiments, tangential flow filtration is used to concentrate the insoluble material (cell debris) with which the *botulinum* complex is associated, while permitting filtrate to pass through the membrane pores. (See, e.g., Figure 1A.) Tangential flow filtration parameters, such as pore size, feed flow, applied pressure, and the like, may be selected by those of skill in the art to concentrate cell debris and to produce a more concentrated sample comprising the *botulinum* toxin A complex. In some particularly preferred embodiments, for example, tangential flow filtration with filters having a pore size of about 0.1 μm may be used.

[0041] In some embodiments, the sample comprising a *botulinum* toxin A is subjected to nuclease digestion. Nuclease digestion can facilitate removal of nucleic acid components with which the *Botulinum* toxin complexes tend to associate. In certain preferred embodiments, nuclease digestion follows tangential flow filtration and is carried out on the concentrated cell debris obtained therefrom. (See, e.g., Figure 1A.) For example, the concentrated cell debris sample may have its pH adjusted to allow nuclease activity and may be incubated with one or more suitable nucleases, such as DNases and/or RNases that digest (hydrolyze) DNA and/or RNA, respectively. Depending on the nuclease enzyme used, suitable pH may be about 5 to about 7, preferably about 6. In some embodiments, benzamidine is used as a protease inhibitor to prevent proteolysis of the toxin during nuclease digestion step. The nuclease used may be derived from any suitable source, including animal sources and/or non-animal sources.

[0042] In more preferred embodiments, the nuclease is obtained from a non-animal source, to provide an animal-product-free nuclease and an animal-product-free process. Accordingly, the instant invention encompasses animal-product-free processes (or substantially or essentially animal product free processes) for purifying *botulinum* toxin which comprise use of a nuclease. An animal-product-free nuclease may be made recombinantly, e.g., using recombinant bacteria, yeasts, or other suitable microorganisms, which have been transformed to express a DNase and/or RNase for use in a nuclease digestion step according to processes described herein. Nuclease digestion typically reduces the nucleic acid content of the sample, as the host cell nucleic acids are degraded and their removal is facilitated. For example, hydrolyzed nucleic acids and other low molecular weight impurities can be removed by further purification steps.

[0043] In certain embodiments, the sample comprising a *botulinum* toxin A may be subjected to clarifying centrifugation and/or filtration. Clarifying centrifugation or filtration refers to centrifugation or filtration steps used to remove gross elements, such as whole and lysed cells and cell debris, from the sample, resulting in a measurably clearer sample. In certain embodiments, the centrifugation is performed at about 10,000xg to about 30,000xg, more preferably at about 15,000xg to about 20,000xg, and most preferably at about 17,700xg. Clarifying filtration will typically comprise normal flow filtration, also called "dead end" filtration, where fluid is moved directly toward a filter media under applied pressure, and particulates too large to pass through the filter pores accumulate at the surface or within the media itself, while smaller molecules pass through as the filtrate. In some particularly preferred embodiments, the sample is mixed with ammonium sulfate and normal flow filtration is performed using a filter with a pore size of about 0.1 to about 0.3 μm , and more preferably a pore size of about 0.2 μm . (See, e.g., Figure 1A.) In certain particularly preferred embodiments, one or more clarifying step(s) follow the nuclease digestion step. In certain still more preferred embodiments, one or more clarifying step(s) immediately precede purification by chromatography.

[0044] Notably, in preferred embodiments, the clarified supernatant or filtrate provides the *botulinum* toxin A-containing sample for use in further purification steps, such as the chromatography purification steps, rather than the insoluble fraction, which is discarded. This is in contrast with the process outlined in Figure 1B, where the *botulinum* toxin complex is contained in the insoluble fraction from pre-chromatography steps that do not involve acid precipitation, such as e.g., as a centrifugation pellet, obtained from pre-chromatography centrifugation, and the supernatant is discarded.

Chromatography Purification Steps

[0045] Figure 1A also illustrates chromatographic purification steps according to certain embodiments of the instant invention. According to one embodiment of the invention, chromatographic methods for purifying a non-complexed *botulinum* toxin A comprise passing a sample comprising *botulinum* toxin A through a plurality of chromatography columns to obtain

a highly purified, highly potent, non-complexed form of the neurotoxin.

[0046] Complexed *botulinum* toxin A is separated from other cellular components using a hydrophobic interaction column (see e.g., Figure 1A). This column captures the *botulinum* toxin in complexed form, while allowing impurities to flow through the column. The column used may be any hydrophobic interaction column known in the art suitable for such purpose, such as Butyl Sepharose Fast Flow column or Phenyl Sepharose HP, commercially available from GE Healthcare Life Sciences. In some embodiments, the method further comprises conditioning the sample for hydrophobic interaction chromatography before loading onto the column. For example, for use in the Phenyl Sepharose HP column, the sample may be combined with a 0.5M ammonium sulfate solution at pH 6, and 50mM phosphate before loading. Other columns, buffers and pH conditions that may be used include columns such as Phenyl Sepharose Fast Flow high substitution, Phenyl Sepharose Fast Flow low substitution, Butyl Sepharose, and Octyl Sepharose; buffers such as acetate, citrate, MES, histidine, piperazine, and malonate, each in the pH range of about 4.0 to about 7.0, more preferably about 4.5 to about 6.5, and even more preferably about 5.5. Other buffer and pH conditions may be determined to optimize yield from a particular column used, as known in the art, based on the teachings provided herein. Without wishing to be bound to theory, it is believed that separation involves binding of the toxin complex to resin at a pH below 7, to avoid dissociation at this step, while allowing many cell-derived impurities to flow through, such as, e.g., smaller proteins, nucleic acids, and the like.

[0047] For eluting the captured (bound) toxin from the hydrophobic interaction column, a suitable buffer can be used, as known in the art. In some particularly preferred embodiments, a descending gradient of ammonium sulfate is used. The concentration range of the descending gradient may be from about 0.6 M to about 0.0 M, about 0.5 M to about 0.0 M, or about 0.4 M to about 0.0 M. Other eluting buffers that may be used include, for example descending gradients of sodium sulfate (Na_2SO_4); sodium chloride (NaCl); potassium chloride (KCl); ammonium acetate (NH_4OAc); and the like. Fraction(s) containing a product peak can be identified, as known in the art. The peak fraction is typically found, e.g., when using ammonium sulfate, in a concentration range of about 0.4 M to about 0.0 M; more preferably about 0.3 M to about 0.0 M; and most preferably about 0.25 M to about 0.0 M ammonium sulfate, while the pH is kept at about 6 to maintain the complex. That is, the fraction(s) containing the eluted *botulinum* toxin A complex can be identified and used in subsequent purification steps.

[0048] In preferred embodiments, the *botulinum* toxin A complex obtained is caused to dissociate to give a non-complexed form. In certain preferred embodiments, the dissociation step is performed after the hydrophobic interaction chromatography step and/or before subsequent chromatography steps (e.g., see Figure 1A). Accordingly, in some preferred embodiments, the instant invention encompasses methods where the chromatographic target molecule differs from one chromatographic step to another. That is, in an initial chromatographic step, the target comprises a *botulinum* toxin A complex, whereas in subsequent chromatographic steps, the target comprises the free *botulinum* toxin A, dissociated from non-toxin proteins such as hemagglutinin and non-hemagglutinin proteins. In

contrast, the process outlined in Figure 1B involves chromatography steps that are all designed to purify *botulinum* toxin complexes.

[0049] Dissociation of the *botulinum* toxin A complex to produce the non-complexed *botulinum* toxin A protein may be achieved in a number of ways, e.g., as known in the art and/or described herein. For example, dissociation may be achieved by raising the pH to about 7.0; or, in embodiments in which animal protein free purification is not necessary, treating the complex with red blood cells at a pH of about 7.3.

[0050] In a preferred embodiment and to provide animal free toxin, the complex is subjected to a separation process based on adjustment pH of the complex in a suitable buffer. Suitable buffers include, but are not limited to, cationic buffers, preferably cationic buffers that will not interact or will not substantially interact with the anion exchange column. Suitable cationic buffers include, e.g., Tris, bis-Tris, triethanolamine, N-methyl diethanolamine. A pH of between about 7 to about 8.4; more preferably between about 7.4 to about 8.2; and most preferably a pH of about 7.8 is typically suitable for dissociating the complex to release the non-complexed botulinum toxin. In some particularly preferred embodiments, for example, the pH of the eluent of the hydrophobic interaction column is raised to about 7.5, about 7.8, or preferably to about 8.0. For example, in some embodiments, the eluent may be diluted into a Tris buffer having a pH of about 7.8 to cause the complex to dissociate into individual components, including the about 150 kD non-complexed *botulinum* toxin A protein. The resulting mixture comprising dissociated components can then be subjected to one or more additional chromatography purification steps, such as ion exchange chromatography steps designed to capture and further purify the non-complexed toxin.

[0051] In certain embodiments according to the invention, the non-complexed *botulinum* toxin A may be purified using one or more ion exchange chromatography steps, (e.g., see Figure 1A). Ion exchange chromatography achieves fractionation based on electrostatic charge. The extent to which a given protein binds to the column matrix is a function of the protein's net charge, based on its individual amino acid composition and the charge of the column matrix. Cationic ion exchange columns have net positive charged matrix whereas anionic ion exchange columns have a net negative charged matrix. Bound proteins can be selectively eluted from the column using a solvent (the eluant) containing a charged substance, such as salt ions, which competes with the charged matrix support for binding to the charged proteins. Bound proteins can be thus fractionated on the basis of the strength of their charge. Alternatively, proteins may be eluted by adjusted the pH which may alter the net charge of the protein thereby altering its affinity to the charged matrix.

[0052] According to some preferred embodiments of the invention, the mixture comprising non-complexed *botulinum* toxin A is loaded onto an anion exchange column (e.g., see Figure 1A). Notably, this column captures the *botulinum* toxin in non-complexed form, such that the toxin protein and dissociated non-toxin proteins can be eluted in separate fractions. The column used may be any anion column known in the art suitable for separating charged proteins, non-limiting examples of which include Q Sepharose HP, Q Sepharose Fast Flow, or

Q XL Sepharose, commercially available from GE Healthcare Life Sciences. In some particularly preferred embodiments, a Q XL Sepharose column is used. In some embodiments, the method further comprises conditioning the mixture comprising the non-complexed *botulinum* toxin A for anion exchange chromatography before loading onto the column. For example, buffer and pH conditions may be determined to optimize yield from the particular column used, as known in the art, based on the teachings provided herein. For loading and use in the column, e.g., suitable buffers include, but are not limited to, cationic buffers, preferably cationic buffers that will not interact or will not substantially interact with the anion exchange column. Suitable cationic buffers include, e.g., Tris, bis-Tris, triethanolamine, N-methyl diethanolamine. For loading and equilibrating the column, a pH of between about 7.2 to about 8.6; more preferably between about 7.4 to about 8.2; and most preferably a pH of about 7.8 may be used.

[0053] For eluting the captured (bound) toxin and other dissociated components from the anion exchange column, a suitable buffer can be used, as known in the art. Examples of suitable buffers include, for example, sodium chloride (NaCl); and potassium chloride (KCl). In some particularly preferred embodiments, an ascending gradient of sodium chloride is used. For example, a sodium chloride buffer having a concentration range from about 0.0 M to about 0.4 M NaCl, more preferably from about 0.0 M to about 0.5 M NaCl, and even more preferably about 0.0 M to about 0.6 M NaCl may be used. Impurities separated in different fractions may include, e.g., one or more non-toxin proteins of the dissociated complex, such as, the non-toxin hemagglutinin and/or non-toxin non-hemagglutinin proteins. Fraction(s) containing a product peak can be identified, as known in the art. The peak may occur, for example, at about 8 mSem to about 22 mSem at a pH between about 7.4 to about 8.4, and preferably at about 7.8, corresponding to about 0.08 M to about 0.18 M NaCl. Conversely, other impurities may elute at about 30 to about 45 mSem, corresponding to about 0.25 M to about 0.35 M NaCl.

[0054] The fraction(s) containing the eluted non-complexed *botulinum* toxin A can be identified to provide an eluent comprising a non-complexed *botulinum* toxin A. The peak may be identified by methods as known in the art, e.g., using HPLC, western blot analysis, ELISA, non-reduced SDS-PAGE, and the like. SDS-PAGE under non-reducing conditions, for example, can identify the about 150 kDa toxin band, whereas other impurities will appear at bands corresponding to smaller molecules. This eluent comprising a non-complexed form may then be subjected to further chromatographic purification steps.

[0055] In one particularly preferred embodiment, toxin purity is assessed by SDS-PAGE. As the skilled artisan will appreciate, SDS-PAGE analysis can be conducted in the absence or presence of agents that cleave disulfide bonds present in the protein (i.e., non-reducing or reducing conditions, respectively). For example, with respect to botulinum toxin type A, the mature and active form of the botulinum toxin type A protein molecule is comprised of two polypeptide chains of 100 kD and 50 kD, respectively, which are held together by non-covalent interactions as well as a disulfide bond. When botulinum toxin type A produced by the inventive process is assayed using non-reducing conditions, the botulinum toxin type A protein molecules migrate as a single protein band of approximately 150 kD and the measured purity

is typically greater than 98%. When the botulinum toxin type A protein amount loaded per gel lane is held to be within the dynamic range of the densitometer, then there are few, if any, detectable impurity bands resulting in a measured purity of 100%. When the type A botulinum toxin is overloaded such that the main toxin band is above the dynamic range of the densitometer, then some minor impurity bands may be detectable (as much as 1-2%).

[0056] However, when the SDS-PAGE analysis of botulinum toxin type A is conducted under reducing conditions, then the disulfide bond of the botulinum toxin is cleaved and the botulinum toxin type A protein migrates as two components having molecular weights of 100 kD and 50 kD, respectively. When the botulinum toxin type A protein is loaded such that the main species are above the dynamic range of the densitometer and the SDS-page is run under reducing conditions then minor impurity species can be more easily detected. For instance, under these conditions there may be as much as 5% of the 150 kD species present due to incomplete proteolytic processing during the fermentation and recovery process. Under these conditions the inventive process yields a toxin product (comprised of the active, cleaved 100 kD and 50 kD polypeptide chains) that is typically greater than 90% of total protein and more likely greater than 95% of total protein. Thus, the reported measured purity of the toxin depends on the details of the SDS-PAGE method employed, as described herein. Furthermore, while the foregoing example concerns botulinum toxin type A, the skilled artisan will appreciate that the SDS-PAGE analysis described herein can be readily adapted to assess the purity of other serotypes of botulinum toxin.

[0057] In certain embodiments, the eluent from the anionic column comprising non-complexed *botulinum* toxin A is loaded onto a cation exchange column (see, e.g. Figure 1A). Notably, this column also captures the *botulinum* toxin in non-complexed form, such that the toxin protein and dissociated non-toxin proteins can be eluted in separate fractions. The column used may be any cation column known in the art suitable for separating proteins, non-limiting examples of which include an SP Sepharose column, including SP Sepharose HP or SP Sepharose Fast Flow; a Mono S column; or a Source-S column, such as a Source-30S column, or preferably a Source-15S column, both commercially available from GE Healthcare Life Sciences. In some embodiments, the method further comprises conditioning the eluent from the anionic exchange columns comprising non-complexed *botulinum* toxin A for cation exchange chromatography before loading onto the column. In some preferred embodiments, the pH is adjusted so that the pH of the eluent being loaded on the column allows for efficient binding of the free toxin to the column. For example, the pH can be maintained within a range of from about 4 to about 8, preferably from about 5 to about 7.5, more preferably from about 6 to about 7, and most preferably at about 7. Further, in some embodiments, the eluent from the anionic column can be treated to reduce conductivity before loading onto the cation exchange column, e.g., using a sodium phosphate buffer, a non-limiting example of which is a sodium phosphate buffer of about 20 mM NaH_2PO_4 . For example, the eluent from the anionic column may contain as much as about 0.15 M NaCl, so that diluting in an about 20 mM NaH_2PO_4 buffer reduces conductivity. In some specific embodiments, conductivity is reduced from about 12 mSem to about 3.3 mSem. Dilution in buffer, dialysis or other methods known in the art also may be used to reduce the conductivity.

[0058] For loading and use in the column, e.g., suitable buffers include, but are not limited to, anionic buffers, preferably anionic buffers that will not interact or will not substantially interact with the cationic exchange column. Suitable anionic buffers include, e.g., as MES, HEPES, and the like, and preferably sodium phosphate buffer. For loading and equilibrating the column, a pH of between about 4 to about 8; preferably between about 5 to about 7.5; more preferably from about 6 to about 7; and most preferably a pH of about 6.8 to about 7 may be used.

[0059] For eluting the captured (bound) toxin from the cation exchange column separately from other dissociated non-toxin proteins and other impurities, a suitable buffer can be used, as known in the art. In some particularly preferred embodiments, an ascending gradient of sodium chloride is used. A suitable concentration range for the sodium chloride gradient may be from about 0.0 M to about 1 M NaCl. Other salts that may be used include, e.g., potassium chloride, that may be used at a concentration gradient of about 0.0 M to about 0.5 M KCl. Fraction(s) containing a product peak can be identified, as known in the art. The peak may occur, for example from about 18 to about 25 mSem, corresponding to about 0.3 M to about 0.4 M NaCl, at a pH of about 6.7. That is, the fraction(s) containing the eluted non-complexed *botulinum* toxin can be identified to provide an eluent from the cationic column comprising non-complexed *botulinum* toxin. In particularly preferred embodiments, the eluent from the cationic column represents a non-complexed *botulinum* toxin A of high purity, in high yield and having high activity. In contrast, the process outlined in Figure 1B provides a 900 kD *botulinum* toxin type A complex in the final eluent.

Purified Non-Complexed Botulinum Toxin Product

[0060] The methods described herein are useful to provide a non-complexed *botulinum* toxin of high purity, in high yield, and having high activity. See Example 1 below. The product is also readily stabilized and conveniently used for the preparation of safe pharmaceutical compositions.

[0061] In some preferred embodiments, the purified non-complexed *botulinum* toxin A is at least about 80% pure, preferably at least about 90% pure, more preferably at least about 95% pure, even more preferably at least about 98% pure, and most preferably at least about 99% pure, or even about 100% pure. "Purified non-complexed *botulinum* toxin" refers to a free *botulinum* toxin protein molecule that is isolated, or substantially isolated, from other proteins and impurities, which can otherwise accompany the non-complexed *botulinum* toxin as it is obtained from a culture or fermentation process. A purified non-complexed *botulinum* toxin that is, for example, "80% pure" refers to an isolated or substantially isolated non-complexed *botulinum* toxin protein wherein the toxin protein comprises 80% of total protein present as determined by or other suitable analytical methodology, non-limiting examples of which include SDS-PAGE, CE, and HPLC. For example, in some preferred embodiments, the cationic column eluent comprising the non-complexed *botulinum* toxin A is at least about 99% pure, and contains less than about 1% of host cell proteins that are not the approximately 150 kD

botulinum toxin originally present.

[0062] In some preferred embodiments, the purified non-complexed *botulinum* toxin A has an activity of at least about 150 LD₅₀ units/ng, preferably at least about 180 LD₅₀ units/ng, more preferably at least about 200 LD₅₀ units/ng, even more preferably at least about 210 LD₅₀ units/ng, and most preferably at least about 220 LD₅₀ units/ng. One unit of *botulinum* toxin is defined as the LD₅₀ upon intraperitoneal injection into female Swiss Webster mice weighing about 18-20 grams each. In other words, one unit of *botulinum* toxin is the amount of *botulinum* toxin that kills 50% of a group of female Swiss Webster mice. "Activity" is used interchangeably herein with related expressions "biological activity", "potency" and "toxicity" to describe the action of a *botulinum* toxin.

[0063] In preferred embodiments, the non-complexed *botulinum* toxin A obtainable by processes described herein demonstrates biological activity. That is, in preferred embodiments, the biological activity or toxicity of the product is not lost upon purification in accordance with preferred embodiments of the present invention, even though non-toxin proteins natively associated with the toxin protein are removed during purification. In even more preferred embodiments, the potency obtained using a given set of processes and parameters within the scope of the invention is consistent and/or reproducible. For example, the potency measurement can be made with less than about 40% variability, preferably less than about 35% variability, more preferably less than about 30% variability, even more preferably less than about 25% variability, and most preferably less than about 20% variability.

[0064] In some preferred embodiments, the purification process provides the non-complexed *botulinum* toxin A in high yield. For example, the yield obtained from 30 L of a fermentation culture may be at least about 30 mg, preferably at least about 40 mg, more preferably at least about 70 mg, even more preferably at least about 80 mg, and most preferably at least about 90 mg, corresponding to a yield of at least about 1 mg/L, preferably at least about 1.3 mg/L, more preferably at least about 2.3 mg/L, even more preferably at least about 2.7 mg/L, and most preferably at least about 3 mg/L, respectively. In even more preferred embodiments, the yield obtained using a given set of processes and parameters within the scope of the invention is reproducible. For example, yield can be measured with less than about 40% variability, preferably less than about 35% variability, more preferably less than about 30% variability, even more preferably less than about 25% variability, and most preferably less than about 20% variability.

[0065] In some particularly preferred embodiments, the purified non-complexed *botulinum* toxin A is stable during purification using the processes described herein. It has been believed that removal of associated non-toxin proteins from a *botulinum* toxin complex, such as *botulinum* toxin type A complex, results in a markedly unstable *botulinum* toxin product. The instant invention, however, provides methods that can stably isolate free *botulinum* toxin, without associated non-toxin proteins conventionally believed necessary during the purification process to maintain stability, as discussed above.

[0066] In some preferred embodiments, methods described herein provide a non-complexed *botulinum* toxin A that requires very few post-chromatography steps, e.g., in terms of maintaining stability during storage, and in terms of applicability to pharmaceutical uses. For example, as known in the art, ammonium sulfate may be added to the free *botulinum* toxin to prepare an ammonium sulfate suspension for storage. The composition comprising free *botulinum* toxin and ammonium sulfate may be readily stored in a refrigerator and later can be readily retrieved for use in pharmaceutical applications. Indeed, the stability, high yield and purity, and high and consistent potency of the toxin obtainable by methods described herein facilitate pharmaceutical use of the purified product, as described in more detail below.

Uses of Purified Non-Complexed Botulinum Toxin

[0067] The non-complexed *botulinum* toxin A purified according to this invention can be used in the preparation of pharmaceutical compositions comprising the toxin as an active ingredient for administration to any subject who would receive a benefit from such pharmaceutical compositions. In preferred embodiments, the subjects to be treated are mammals, preferably humans. "Pharmaceutical composition" as used herein refers to a formulation in which an active ingredient can be a *botulinum* toxin. The formulation will contain at least one additional ingredient and be suitable for diagnostic, therapeutic, and/or or cosmetic administration to a subject, such as a human patient. The pharmaceutical composition can be liquid or solid; and may be a single or multi-component system, for example a lyophilized composition reconstituted with a diluent such as saline.

[0068] Another aspect of the disclosure provides for administration of a purified botulinum toxin molecule to a patient. "Administration" as used herein refers to providing a pharmaceutical composition to a subject or patient. The pharmaceutical composition may be administered by, any method known in the art, including e.g., intramuscular (i.m.), intradermal, intranasal, or subcutaneous administration, intrathecal administration, intracranial, intraperitoneal (i.p.) administration, or topical (transdermal) and implantation (e.g., of a slow-release device) routes of administration. In certain preferred aspects, the purified non-complexed botulinum toxin is administered topically or by injection in compositions as described in U.S. Patent Application Nos. 09/910,432; 10/793,138; 11/072,026; 11/073,307, 11/824,393, and 12/154,982.

[0069] In certain embodiments, compositions comprising non-complexed *botulinum* toxin in an ammonium sulfate suspension can be readily compounded into a pharmaceutical composition. For example, an ammonium sulfate suspension comprising non-complexed *botulinum* toxin protein can be centrifuged to recover the protein and the protein can be re-solubilized, diluted, and compounded with one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical composition may comprise a non-complexed *botulinum* toxin as an active pharmaceutical ingredient, and may further comprise one or more buffers, carriers, stabilizers, preservatives and/or bulking agents. The pharmaceutical compositions may be lyophilized to powder for storage, and re-constituted for further use. Accordingly,

processes and systems described herein can provide a *botulinum* toxin in a form particularly suited to pharmaceutical applications terms of ease of preparation.

[0070] The pharmaceutical composition may find use in therapeutic, diagnostic, research and/or cosmetic applications. For example, as discussed above, *botulinum* toxin type A is clinically used to treat neuromuscular disorders characterized by skeletal muscle hyperactivity, such as essential blepharospasm, strabismus, cervical dystonia, and glabellar line (facial) wrinkles. Moreover, in certain applications, non-complexed (about 150 kD) *botulinum* toxin is the preferred form for treating humans. See, e.g., Kohl A., et al., Comparison of the effect of botulinum toxin A (Botox®) with the highly-purified neurotoxin (NT 201) in the extensor digitorum brevis muscle test, *Mov Disord* 2000; 15(Suppl 3): 165. Accordingly, certain *botulinum* toxin pharmaceutical compositions are preferably prepared using non-complexed *botulinum* toxin, as opposed to a *botulinum* toxin complex.

EXAMPLES

Example 1: Comparison of Inventive Process with a Modified Schantz Process

[0071] Purifications of non-complexed *botulinum* toxin type A using processes within the scope of the instant invention ("inventive process") were directly compared to purifications based on the traditional Schantz approach, further modified by the addition of chromatographic steps to provide the non-complexed form (Modified Schantz process"). Briefly, *Clostridium botulinum* bacteria were cultured and allowed to grow until fermentation was complete (usually about 72 to about 120 hours from inoculation to harvest). A volume of 30 L of the fermentation culture then was used in each of the following purification procedures.

[0072] The modified Schantz process used involved typical acidification of the fermentation culture to precipitate the toxin, followed by ultramicrofiltration (UF) and diafiltration (DF) to concentrate the raw toxin. DNase and RNase were added to the harvested toxin to digest (hydrolyze) nucleic acids, which were then removed by an additional UF step, using tangential flow filtration (300kD UF). The toxin was next extracted with phosphate buffer, followed by three sequential precipitation steps: cold ethanol precipitation; hydrochloric acid precipitation, and ammonium sulfate precipitation, where the supernatants each time were normally discarded. This procedure provided a 900 kD *botulinum* toxin type A complex, which was then subjected to additional chromatography steps to provide the free toxin. Specifically, the toxin complex was resolubilized and subjected to negative batch adsorption onto a DEAE resin. The eluent was then run on a gravity flow anion exchange column (DEAE-Sepharose), followed by a gravity flow cation exchange column (CM-Sepharose). Yield was determined, the length of time the process took was recorded (not counting the fermentation period), and the purified non-complexed *botulinum* toxin type A was measured for purity by SDS-PAGE analysis and assayed for potency, e.g., by techniques known to those skilled in the art. The entire modified

Schantz process was repeated for three different lots, lot numbers 1, 2 and 3, and the results recorded in Table 1 below.

[0073] The inventive process was used with three different lots, lot numbers 4, 5 and 6, in accordance with systems and methods described herein. Briefly, the fermentation culture was subjected to acid precipitation using 3M sulfuric acid to reduce pH to 3.5, at a temperature below 25°C. The acid precipitate was then subjected to 0.1 µm tangential flow filtration to concentrate cell mass. The pH then was adjusted to 6 and nucleases added to reduce host cell nucleic acid content, followed by clarification by centrifugation to remove cell debris and dead end filtration at 0.2 µm with added ammonium sulfate. The filtrate was then directly loaded onto the hydrophobic interaction column, Phenyl Sepharose HP (GE Life Sciences), eluted with a descending gradient of ammonium sulfate, and the product peak isolated. The eluent was then diluted into Tris buffer pH 7.8 to dissociate the toxin complex, which then was loaded onto the anion exchange column Q XL Sepharose (GE Lifesciences), eluted with an ascending gradient of sodium chloride, and again the product peak collected. This eluent was then diluted in a sodium phosphate buffer (to reduce conductivity) and loaded onto either the anion exchange column, Q XL Sepharose (for lots # 4 and 5), or the cation exchange column, Source-S (GE Life Sciences) (for lot #6), again eluted with an ascending gradient of sodium chloride, and a final product peak collected and stored. This process yielded non-complexed *botulinum* toxin type A. Yield was determined, the length of process time recorded (not counting the fermentation period), and the toxin measured for purity by SDS-PAGE analysis and assayed for potency, e.g., by techniques known to those skilled in the art. Results also recorded Table 1 below.

Table 1

	Modified Schantz Process			Inventive Process		
Lot #	1	2	3	4	5	6
Process Time	10 days			4 days		
% Purity	99	n/a	97	98.6	95.3	100
Yield (30L scale)	11 mg	0 mg	4 mg	43 mg	99 mg	89 mg
Potency (LD50 Units/Ing)	255	n/a	173	259	252	250

[0074] As Table 1 indicates, there was a lot failure with respect to lot #2 in the modified Schantz process. The total lot failed giving zero yield. There was also a partial lot failure with respect to lot #3. There the failure occurred at the hydrochloric acid precipitation step, but some product was rescued from the normally discarded supernatant. The rescued product was reprocessed with a deviation step, accounting for the observed reduced yield compared with lot #1 (4 mg compared with 11 mg) and the observed reduced potency compared with lot #1 (173 LD50 units/ng compared with 255 LD50 units/ng).

[0075] With respect to the lots used with the inventive process, lot #4 showed a reduced yield, compared to lot #5 for example (43 mg compared with 99 mg) due to a chromatography

system failure, involving high salt wash of a column. With the failure, there was premature elution of a portion of the toxin, resulting in the observed reduced yield, but also an observed higher purity (98.6 % purity compared with 95.3% purity).

[0076] Lot #6 represents the results of a highly preferred embodiment of the instant inventive processes and systems, where a cation exchange column was used in the third chromatography step. As Table 1 indicates, this embodiment resulted in improved purity compared with lot #5 for example (100% purity compared with 95.3% purity), while high yield (89 mg compared with 99 mg) and high potency (250 LD50 units/ng compared with 252 LD50 units/ng) were maintained.

[0077] As Table 1 also indicates, the total length of the purification can be shortened in preferred embodiments of the instant invention. For example, lot #6 was purified within only 4 days, compared to the 10 days it took to purify non-complexed *botulinum* toxin using the modified Schantz method that involved three additional chromatography steps after the conventional Schantz method.

[0078] The results indicate that the processes and systems taught herein can be used to prepare high yields of a non-complexed *botulinum* toxin, at high potency and purity, and suggests that methods and systems described herein can find use in large-scale efficient purification of a non-complexed *botulinum* toxin suitable for use, e.g., as an active ingredient in pharmaceutical compositions.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US61253810](#) [0001]
- [US20030008367A](#) [0006]
- [US7452697B](#) [0008] [0036]
- [US7354740B](#) [0008] [0036]

- [US20060228780A1](#) [0008]
- [US910432A](#) [0068]
- [US10793138B](#) [0068]
- [US11072026B](#) [0068]
- [US11073307B](#) [0068]
- [US11824393B](#) [0068]
- [US12154982B](#) [0068]

Non-patent literature cited in the description

- **SCHANTZ E. J et al.** Properties and use of botulinum toxin and other microbial neurotoxins in medicine *Microbiol Rev*, 1992, vol. 6, 180-99 [0006]
- **SCHMIDT J. J et al.** Purification of type E botulinum neurotoxin by high-performance ion exchange chromatography *Anal. Biochem.*, 1986, vol. 156, 1213-219 [0006]
- Isolation and characterization of the botulinum neurotoxins **SIMPSON L. L et al.** *Methods in Enzymology* vol. 165, [0006]
- *Microbial Toxins: Tools in Enzymology* Academic Press 1988 0000 vol. 165, 76-85 [0006]
- **KANNAN K et al.** Methods development for the biochemical assessment of Neurobloc (botulinum toxin type B) *Mov Disord*, 2000, vol. 15, 202000- [0006]
- **WANG Y.C.** The preparation and quality of botulinum toxin type A for injection (BTXA) and its clinical use *Dermatol Las Faci Cosm Surg*, 2002, vol. 58, 2002- [0006]
- **ZHOU L. et al.** Expression and purification of the light chain of botulinum neurotoxin A: A single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain *Biochemistry*, 1995, vol. 34, 4615175-81 [0007]
- **JOHNSON S. K. et al.** Scale-up of the fermentation and purification of the recombination heavy chain fragment C of botulinum neurotoxin serotype F, expressed in *Pichia pastoris* *Protein Expr and Purif*, 2003, vol. 32, 1-9 [0007]
- **GESSLER** *Journal of Biotechnology*, 2005, vol. 119, 204-211 [0008]
- **SCHANTZ E. J. et al.** Properties and use of botulinum toxin and other microbial neurotoxins in medicine *Microbiol Rev*, 1992, vol. 56, 180-99 [0033]
- Preparation and characterization of botulinum toxin type A for human treatment **SCHANTZ E. J. et al.** *Neurological Disease and Therapy. Therapy with botulinum toxin* Marcel Dekker 1994 0000 41-49 [0033]
- Use of crystalline type A botulinum toxin in medical research **SCHANTZ E. J et al.** *Biomedical Aspects of Botulism* Academic Press 1981 0000 143-50 [0033]
- **KOHL A et al.** Comparison of the effect of botulinum toxin A (Botox®) with the highly-purified neurotoxin (NT 201) in the extensor digitorum brevis muscle test *Mov Disord*, 2000, vol. 15, 3165- [0070]

PATENTKRAV

1. Fremgangsmåde til oprensning af et ikke-kompleksbundet *botulinum* toksin type A (*botulinum* toksin A), hvilken fremgangsmåde omfatter:

5 (i) tilvejebringelse af en blanding, der omfatter en rå, ikke-kompleksbundet *botulinum* toksin A, hvor den rå, ikke-kompleksbundne *botulinum* toksin A dissocieres fra native, ikke-toksiske proteiner, hvor blandingen opnås ved;

(a) udsættelse af en fermenteringskultur, der omfatter *botulinum* toksin A, for syreudfældning for at opnå en syreudfældning; og udførelse af tangentielt
10 strømningsfiltrering på præcipitatet for at frembringe en opkoncentreret prøve;

(b) fyldning af en hydrofob interaktionssøjle med prøven for således at muliggøre opfangning af *botulinum* toksin A-komplekset med den hydrofobe interaktionssøjle;

(c) eluering af *botulinum* toksin A-komplekset fra den hydrofobe
15 interaktionskromatografisøjle;

(d) dissociering af *botulinum* toksin A-komplekset for at opnå en blanding, der omfatter det rå, ikke-kompleksbundne *botulinum* toksin A.

(ii) fyldning af det rå, ikke-kompleksbundne *botulinum* toksin A på en anionbyttersøjle for således at muliggøre opfangning af det ikke-kompleksbundne
20 *botulinum* toksin A ved hjælp af anionbyttersøjlen;

(iii) eluering af det ikke-kompleksbundne *botulinum* toksin A fra anionbyttersøjlen for at opnå en eluent, der omfatter det ikke-kompleksbundne *botulinum* toksin A;

(iv) fyldning af en kationbyttersøjle with eluenten fra anionbyttersøjlen for
25 således at muliggøre opfangning af det ikke-kompleksbundne *botulinum* toksin A ved hjælp af kationbyttersøjlen; og

(v) eluering af oprenset ikke-kompleksbundet *botulinum* toksin A fra kationbyttersøjlen.

2. Fremgangsmåde ifølge krav 1, hvor:

(a) prøven er en ovenstående cellevæske eller et filtrat, der omfatter *botulinum* toksin A-komplekset; eller

(b) prøven, der omfatter et *botulinum* toksin A-kompleks, udsættes for en nukleasedigestion før fyldning på den hydrofobe interaktionssøjle, og eventuelt hvor
5 nukleasen afledes af en proces fri for animalsk produkt.

3. Fremgangsmåde ifølge krav 2, hvor prøven, der omfatter et *botulinum* toksin A-kompleks, opnås ved at udsætte en uopløselig fraktion af en fermenteringskultur for tangentiell strømningfiltrering.

4. Fremgangsmåde ifølge krav 1, hvor:

10 (a) fremgangsmåden i alt væsentligt er fri for animalsk produkt, eller

(b) fremgangsmåden giver et udbytte på mindst ca. 2 mg/L fermenteringskultur.

5. Fremgangsmåde ifølge krav 1, hvor:

(a) det oprensede, ikke-kompleksbundne *botulinum* toksin A er mindst 95 %
15 rent; eller

(b) det oprensede, ikke-kompleksbundne *botulinum* toksin A har en aktivitet på mindst 200 LD₅₀ enheder/ng.

6. Fremgangsmåde ifølge krav 1, hvor den anioniske søjle er valgt fra gruppen bestående af en Q Sepharose HP-, Q Sepharose Fast Flow- og Q XL
20 Sepharose-søjle, og hvor den kationiske søjle er valgt fra gruppen bestående af en SP Sepharose-, SP Sepharose HP-, SP Sepharose Fast Flow-, Mono S-, Source-S-, Source-30S- og Source-15S-søjle.

7. Fremgangsmåde ifølge krav 1, hvor en buffer til fyldning af det rå, ikke-kompleksbundne *botulinum* toksin A på den anioniske søjle er valgt fra gruppen
25 bestående af Tris, bis-Tris, triethanolamin og N-methyldiethanolamin, og eventuelt hvor bufferen anvendes ved et pH fra 7,4 til 8,2.

8. Fremgangsmåde ifølge krav 1 hvor en buffer for fyldning af det rå, ikke-kompleksbundne *botulinum* toksin A på den kationiske søjle er valgt fra gruppen

bestående af natriumphosphat, MES, og HEPES, og eventuelt hvor bufferen anvendes ved et pH fra 6,0 til 7,0

9. Fremgangsmåde ifølge krav 1, hvor den anioniske søjles pH er fra 7,4 til 8,2.

5 **10.** Fremgangsmåde ifølge krav 1, hvor den kationiske søjles pH er fra 6,0 til 7,0.

11. Fremgangsmåde ifølge krav 1, hvor en gradient til eluering af det ikke-kompleksbundne *botulinum* toksin A fra anionbyttersøjlen er valgt fra gruppen bestående af en stigende koncentrationsgradient af natriumchlorid og en stigende
10 koncentrationsgradient af kaliumchlorid, og eventuelt hvor anionbyttersøjlen elueres ved et pH fra 7,4 til 8,4.

12. Fremgangsmåde ifølge krav 1, hvor en gradient til eluering af det ikke-kompleksbundne *botulinum* toksin A fra kationbyttersøjlen er valgt fra gruppen bestående af en stigende koncentrationsgradient af natriumchlorid og en stigende
15 koncentrationsgradient af kaliumchlorid, og eventuelt hvor kationbyttersøjlen elueres ved et pH fra 6,0 til 7,0.

13. Fremgangsmåde til oprensning af et ikke-kompleksbundet *botulinum* toksin type A (*botulinum* toksin A), hvilken fremgangsmåde omfatter:

(a) tilvejebringelse af en blanding, der omfatter en rå, ikke-kompleksbundet
20 *botulinum* toksin A, hvori den rå, ikke-kompleksbundne *botulinum* toksin A dissocieres fra native ikke-toksinproteiner; hvor blandingen opnås ved:

(i) udsættelse af en fermenteringskultur, der omfatter *botulinum* toksin A, for syreudfældning for at frembringe en uopløselig syreudfældning;

(ii) opkoncentrering af syreudfældningen fra trin (i) ved hjælp af tangential
25 strømningsfiltrering for at frembringe en opkoncentreret prøve;

(iii) udsættelse af prøven for nukleasedigestion under forhold, der reducerer værtselle-nukleinsyreindhold og som bevarer et kompleks af *botulinum* toksin A og ikke-toksinproteiner;

(iv) fjernelse af nedbrudt cellemateriale fra prøven fra trin (iii) ved hjælp af centrifugering og/eller filtrering for at frembringe en klaret prøve;

(v) fyldning af en hydrofob interaktionssøjle med den klarede prøve fra trin (iv) under forhold, der muliggør opfangning af *botulinum* toksin A-komplekset ved
5 hjælp af den hydrofobe interaktionssøjle og urenheders strømning gennem søjlen;

(vi) eluering af *botulinum* toksin A-komplekset fra den hydrofobe interaktionssøjle fra trin (iv); og

(vii) dissociering af *botulinum* toksin A-komplekset opnået fra trin (vi) under forhold, der bryder komplekset og producerer en blanding, der omfatter rå, ikke-
10 kompleksbundet *botulinum* toksin A dissocieret fra de native ikke-toksinproteiner;

(b) fyldning af blandingen, der indeholder det rå, ikke-kompleksbundne *botulinum* toksin A dissocieret fra native ikke-toksinproteiner fra trin (a) på en anionbyttersøjle under forhold, der muliggør opfangning af det ikke-kompleksbundne *botulinum* toksin A ved hjælp af anionbyttersøjlen;

15 (c) eluering af det ikke-kompleksbundne *botulinum* toksin A fra anionbyttersøjlen fra trin (b) for at opnå en eluent, der omfatter det ikke-kompleksbundne *botulinum* toksin A;

(d) fyldning af en kationbyttersøjle med eluenten fra anionbyttersøjlen fra trin (c) under forhold, der muliggør opfangning af det ikke-kompleksbundne *botulinum*
20 toksin A ved hjælp af kationbyttersøjlen; og

(e) eluering af oprenset, ikke-kompleksbundet *botulinum* toksin A fra kationbyttersøjlen fra trin (d).

14. Fremgangsmåde ifølge krav 13, hvor, i trin (i), fermenteringskulturen, der omfatter *botulinum* toksin A, syreudfældes med ca. 3M svovlsyre.

25 **15.** Fremgangsmåde ifølge krav 14, hvor prøven fra trin (iii) udsættes for nukleasedigestion ved et pH på 5 til 7.

16. Fremgangsmåde ifølge krav 15, hvor nukleasen afledes af en ikke-animalsk kilde.

DRAWINGS

Drawing

Figure 1A




Figure 1B




Figure 1